EMA Advises Against AstraZeneca Vaccine for Individuals with Capillary Bleeding Syndrome

The European Medicines Agency (EMA) has issued guidance advising against the use of the AstraZeneca查看公司主页 COVID-19 (搜索)搜索该疾病 vaccine in individuals diagnosed with capillary bleeding syndrome (搜索)搜索该疾病. This recommendation stems from concerns that the vaccine may exacerbate the condition, potentially leading to adverse health outcomes.

The Committee for the Safety of Medicinal Products of the EMA has determined that capillary bleeding syndrome (搜索)搜索该疾病 should be listed as a potential side effect of the AstraZeneca vaccine (搜索)搜索该药品. Capillary bleeding syndrome is a rare condition characterized by bleeding from small veins within muscles and body cavities. Symptoms include swelling and a decrease in blood pressure, posing significant health risks to affected individuals.

In addition to the AstraZeneca vaccine (搜索)搜索该药品, the EMA is broadening its investigation into reports of myocarditis (搜索)搜索该疾病 and pericarditis (搜索)搜索该疾病 following vaccination with other COVID-19 (搜索)搜索该疾病 vaccines, including those developed by Pfizer查看公司主页, Moderna查看公司主页, and Johnson & Johnson查看公司主页. Myocarditis and pericarditis are inflammatory conditions affecting the heart muscle and the sac surrounding the heart, respectively.

Data emerging from the United States and Israel have suggested a potential association between mRNA vaccines (Pfizer查看公司主页 and Moderna查看公司主页) and an elevated incidence of myocarditis (搜索)搜索该疾病 and pericarditis (搜索)搜索该疾病, particularly among younger males. These findings have prompted further scrutiny and ongoing investigation by regulatory agencies worldwide.